Copenhagen, Denmark; September 22, 2020 – Genmab A/S (Nasdaq: GMAB) today announced that it has commenced firm arbitration proceedings on two issues arising from its licensing agreement with Janssen Biotech, Inc. (Janssen) regarding daratumab. As part of the licensing agreement, Genmab is entitled to Janssen royalties for the sale of daratumumab (marketed as DARZALEX® for intravenous administration and in the United States as DARZALEX FASPRO™ for subcutaneous administration). « We are very excited to make a new innovation with Janssen and look forward to working with them to accelerate the development of daratumumab and maximize the value of this product, » said Jan van de Winkel, PhD, Chief Executive Officer of Genmab. « This agreement significantly strengthens our financial position and allows Genmab to continue to develop much-needed differentiated antibody drugs to help cancer patients. » About Genmab Genmab is a publicly traded international biotechnology company specializing in the development and development of differentiated antibody therapy drugs for the treatment of cancer. The company, founded in 1999, is the creator of the following authorized antibodies: DARZALEX® (daratumumab, as part of the agreement with Janssen Biotech, Inc.) for the treatment of certain multiple indications of myeloma in regions such as the United States, Europe and Japan, Kesimpta® (atumumab subsanement, as part of the agreement with Novartis AG), for the treatment of adults with multiple sclerosis in the United States and TEPEZZA® (teprotumumab, licensed by Horizon Therapeutics plc) for the treatment of thyroid diseases in the United States. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in the United States and Europe, has been approved in the United States and Europe for the treatment of adult patients with certain indications of multiple myeloma. The first approved vonmab dernotherapy, Arzerra® (ofatumumab, in agreement with Novartis AG), approved for the treatment of certain chronic indications of lymphocytic leukemia, is available in Japan and is also available in other areas via compassionate use or oncology programs. Daratumumab is in clinical development for the treatment of other indications of multiple myeloma, other blood cancers and amylosis. Genmab also has a large pipeline of clinical and preclinical products. Genmab`s technology base consists of validated and proprietary next-generation antibody technologies – the duobody platform® for the production of bi-specific antibodies, the HexaBody platform® which produces strengthened antibodies, the HexElect platform®, which combines two co-dependent hexabody molecules to introduce selective active ingredients while maximizing therapeutic power, and the DuoHexaBody® platform that enhances the potential power of bi-specifics.